How Does Zirgan Work? Mechanism of Action Explained in Plain English

When your doctor prescribes Zirgan (ganciclovir ophthalmic gel 0.15%), you might wonder: how does a gel in my eye actually stop a viral infection? The answer involves a clever biological trick that lets Zirgan target the virus while leaving your healthy eye cells mostly unharmed.

Here's the mechanism of action explained in plain language.

What Is Ganciclovir?

Ganciclovir is the active ingredient in Zirgan. It belongs to a class of drugs called nucleoside analogs — synthetic molecules that mimic the building blocks (nucleosides) used to build DNA. Ganciclovir specifically mimics guanosine, one of the four DNA building blocks.

Viruses like herpes simplex need to copy their DNA to reproduce and spread. By mimicking a DNA building block, ganciclovir can interfere with this copying process — but only in cells where the virus is actively replicating.

Step 1: Activation by a Viral Enzyme

Ganciclovir by itself is relatively inactive. To work, it needs to be converted into its active form — ganciclovir triphosphate — through a process called phosphorylation (adding phosphate groups).

Crucially, the first and most important phosphorylation step is performed by a viral enzyme called thymidine kinase (TK) — an enzyme that only exists in cells infected by herpes simplex virus. Uninfected cells have very little ability to perform this first step, which is why ganciclovir is relatively selective: it only becomes highly active inside virus-infected cells.

This is the key reason Zirgan is considered safer for the ocular surface than older antivirals like trifluridine, which are activated non-selectively and can damage healthy corneal cells.

Step 2: Blocking DNA Replication (Two Ways)

Once converted to ganciclovir triphosphate inside an infected cell, it interferes with viral DNA replication in two complementary ways:

Competitive inhibition of viral DNA polymerase: Ganciclovir triphosphate competes with the normal DNA building block (deoxyguanosine triphosphate) for the virus's DNA-copying enzyme (viral DNA polymerase). By blocking the enzyme's active site, it slows down viral DNA synthesis.

DNA chain termination: When ganciclovir triphosphate is actually incorporated into the growing viral DNA strand, it acts as a 'chain terminator' — the DNA strand cannot be extended further, halting replication entirely.

The result: the herpes simplex virus can no longer make copies of itself. Without new viral particles being produced, the infection stops spreading through your corneal tissue and the body's immune system can eliminate the existing virus.

Why Does It Work Specifically on Herpes Simplex Virus?

Ganciclovir has broad activity against herpesviruses in general. This includes:

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2)

Cytomegalovirus (CMV)

Epstein-Barr virus (EBV)

Varicella zoster virus (VZV)

Human herpesviruses 6 and 7

These viruses all encode their own thymidine kinase, which is what allows ganciclovir to be selectively activated in infected cells. Importantly, ganciclovir does NOT work against bacteria, fungi, or non-herpesvirus infections — it is specifically an antiviral for the herpesvirus family.

Does Zirgan Kill the Herpes Virus Completely?

No — this is an important distinction. Zirgan suppresses viral replication but does not eliminate herpes simplex virus from your body. HSV-1 establishes lifelong latency in sensory nerve ganglia (specifically the trigeminal ganglion for eye infections). Zirgan treats the active infection at the eye surface, allowing the corneal ulcer to heal. Once treatment ends, the virus returns to a dormant state in the nerve cells.

Recurrences are possible and common — approximately 25% of patients with herpetic keratitis will have a recurrence within 2 years. For patients with frequent recurrences, oral antivirals (acyclovir or valacyclovir) can be used as long-term suppressive therapy, as demonstrated in the Herpetic Eye Disease Study (HEDS).

How Quickly Does Zirgan Start Working?

Zirgan works locally at the eye surface with essentially no systemic absorption (maximum daily dose 0.375 mg — less than 0.04% of the oral maintenance dose). It begins interfering with viral replication immediately upon application. Clinical studies show that most patients achieve healed dendritic ulcers within 7 days of starting treatment.

Now that you know how Zirgan works, see our complete guide: What Is Zirgan? Uses, Dosage, and What You Need to Know. If you're having trouble finding it at your pharmacy, medfinder can help you locate it.